|
The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer
RECRUITINGSponsored by Anhui Provincial Hospital
Actively Recruiting
SponsorAnhui Provincial Hospital
Started2024-12-01
Est. completion2026-12-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06737588
Summary
The goal of this study is to evaluate the diagnostic value of different ADC values (incuding ADCmin, ADCmean, ADCratio and ADCrange) of bpMRI in patients with PI-RADS 3-5. The main aim is to evaluate whether different ADC values improve the diagnosis of clinically significant prostate cancer (Gleasonscore≥3+4, ISUP grade ≥2) and any-grade prostate cancer (Gleasonscore≥3+3, ISUP grade ≥1).
Eligibility
Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria: 1. The patient met at least one indication of prostate biopsy (Chinese expert consensus on prostate biopsy (2022 edition) https://rs.yiigle.com/cmaid/1442948 ); 2. Serum PSA test was completed in the patient with tPSA \< 100 ng/ml; 3. Primary prostate tumor lesion, no history of other tumors; 4. Completed 3.0T bpMRI examination, PI-RADS score ≥3 score, the image is clear and readable; 5. Patients fully understand the relevant contents of the study and voluntarily sign the informed consent. Exclusion Criteria: 1. The patient has contraindications for MRI; 2. PI-RADS 1-2 of bpMRI; 3. The patient had contraindications to prostate biopsy or explicitly refused biopsy; 4. bpMRI indicated that the patient had multiple lymph nodes or bone metastases; 5. Previous prostate-related surgery; 6. The patient refused to sign the informed consent.
Conditions2
CancerProstate Cancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorAnhui Provincial Hospital
Started2024-12-01
Est. completion2026-12-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06737588